Journal
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 16, Issue 4, Pages 385-392Publisher
WILEY
DOI: 10.1002/pds.1297
Keywords
treat-to-target; fire-and-forget; statin prescribing
Funding
- Medical Research Council [G106/1249] Funding Source: Medline
- MRC [G106/1249] Funding Source: UKRI
- Medical Research Council [G106/1249] Funding Source: researchfish
Ask authors/readers for more resources
Background There is considerable evidence that statins can reduce cardiovascular events. Currently high-risk patients are treated to a target cholesterol concentration. An alternative prescribing strategy (the 'fire-and-forget' approach) would instead deploy low-dose statins more widely. It has been suggested that for the same cost this approach might prevent more cardiovascular events. We have compared the treat-to-target and fire-and-forget statin prescribing strategies with respect to adherence and cardiovascular outcomes. Methods We used a population-based record-linkage database containing several data sets linked by a unique patient identifier. We identified two cohorts of patients. Patients in the treat-to-target cohort were prescribed a statin, and subsequent measurement of their cholesterol was followed by upward titration of their statin dose if necessary. Patients in the fire-and-forget cohort were prescribed a statin, but no further cholesterol measurement was observed during the follow-up period. Findings Adherence to statin treatment inpatients treated to target was significantly better than in patients treated on a fire-and-forgct basis (adjusted odds ratio 2.51, 95%Cl 2.26-2.78). We found a lower cardiovascular disease (CVD) event rate in patients treated to target than in fire-and-forget patients (hazard ratio of CVD or cardiovascular death 0.41 (0.35-0.48) even after adjustment was made for adherence and baseline CVD risk). Interpretation Our findings suggest that adherence to statins is worse in patients treated on a fire-and-forget basis than in patients treated to a target cholesterol concentration, and that this prescribing strategy is associated with worse cardiovascular outcomes. Copyright (c) 2006 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available